QT time prolongation
Adverse drug events
Variants ✨For the computationally intensive evaluation of the variants, please choose the paid standard subscription.
Explanations of the substances for patients
We have no additional warnings for the combination of ribociclib and abarelix. Please also consult the relevant specialist information.
The reported changes in exposure correspond to the changes in the plasma concentration-time curve [ AUC ]. We do not expect any change in exposure for ribociclib, when combined with abarelix (100%). We do not expect any change in exposure for abarelix, when combined with ribociclib (100%).
The pharmacokinetic parameters of the average population are used as the starting point for calculating the individual changes in exposure due to the interactions.
The bioavailability of ribociclib is unknown. The terminal half-life [ t12 ] is rather long at 32 hours and constant plasma levels [ Css ] are only reached after more than 128 hours. The protein binding [ Pb ] is rather weak at 70%. The metabolism mainly takes place via CYP3A4.
The bioavailability of abarelix is unknown. The terminal half-life [ t12 ] is rather long at 316.8 hours and constant plasma levels [ Css ] are only reached after more than 1267.2 hours. The protein binding [ Pb ] is 97.5% strong. The metabolism via cytochromes is currently still being worked on.
|Serotonergic Effects a||0||Ø||Ø|
Rating: According to our knowledge, neither ribociclib nor abarelix increase serotonergic activity.
|Kiesel & Durán b||0||Ø||Ø|
Rating: According to our knowledge, neither ribociclib nor abarelix increase anticholinergic activity.
QT time prolongation
Rating: In combination, ribociclib and abarelix can potentially trigger ventricular arrhythmias of the torsades de pointes type.
General adverse effects
|Side effects||∑ frequency||rib||aba|
Cough (18.5%): ribociclib
Interstitial lung disease: ribociclib
Pruritus (15%): ribociclib
Stevens johnson syndrome: ribociclib
Toxic epidermal necrolysis: ribociclib
Lymphocytopenia (7%): ribociclib
Anemia (2%): ribociclib
Neutropenia (1.5%): ribociclib
Syncope (1.6%): ribociclib
Sudden cardiac death: ribociclib
Based on your answers and scientific information, we assess the individual risk of undesirable side effects. These recommendations are intended to advise professionals and are not a substitute for consultation with a doctor. In the restricted test version (alpha), the risk of all substances has not yet been conclusively assessed.
No literature information available.